Soluble in DMSO; soluble up to about 2mg/ml in water.
Storage and Stability:
May be stored at RT for short-term only. Long-term storage is recommended at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Form: Supplied as a purple powder.
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Egorin, M.J., et al. "Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats." Cancer Chemother. Pharmacol. 49:7-19 (2002). 2. Tian, Z.Q., et al. "Synthesis and biological activities of novel 17-aminogeldanamycin derivatives." Bioorg. Med. Chem. 12:5317-5329 (2004). 3. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10:4813-4821 (2004). 4. Bull, E.E., et al. "Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin." Clin. Cancer Res. 10:8077-8084 (2004). 5. Hollingshead, M., et al. "In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative." Cancer Chemother. Pharmacol. 56:115-125 (2005).|
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|